Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Mani Foroohar

Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback

Shares of Scholar Rock reversed and closed in the green Tuesday after the FDA rejected the company's spinal muscular atrophy drug.

Investors Business Daily

RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles.

BioNTech stock skidded Wednesday after the Food and Drug Administration ended its broad authorization of Covid vaccines in the U.S.

Investors Business Daily

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Wipes Out Its Recent Rally As It Faces Another Vaccine Setback

Moderna stock toppled Wednesday after the company withdrew its application for a combination Covid and flu vaccine.

Investors Business Daily

BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations

BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.

Investors Business Daily

Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal

Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome study.

Investors Business Daily

Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer

Alnylam stock tumbled Thursday after a split advisory panel recommended the Food and Drug Administration approve its heart disease treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Moderna Crumbles As Cancer Vaccine Data Show A 'Longish And Complex' Road

Moderna stock crumbled Monday after updated results for its Merck-partnered cancer vaccine show a "longish and complex path" toward approval.

Investors Business Daily

Moderna Stock Skids Below Key Line On Unexpected Flu Shot Debacle

Moderna stock skidded Tuesday on a mixed update for its mRNA-based flu vaccine. The update could impact the shot's commercial timing.

Investors Business Daily

Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees

Moderna stock toppled Friday on mixed results for its flu shot — a rival to experimental vaccines from BioNTech, CureVac and Sanofi.

Investors Business Daily

Pfizer Quadruples Its Covid Shot Price — And Other Vaccine Stocks Rocket

Moderna snagged an upgrade Friday on views it will hike charges for its Covid vaccine, as Pfizer plans to charge up to $130 for its shot.

Investors Business Daily

Moderna Climbs On Updated Booster Data, But Analyst Says It Needs A 'Second Act'

Moderna stock popped Wednesday after its updated Covid booster generated a strong antibody response against the omicron variant.

Investors Business Daily

Moderna Rallies After Q4 Earnings: What 2 Analysts Have To Say About COVID-19 Stock

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.